Identifying therapeutic biomarkers of zoledronic acid by metabolomics

Zoledronic acid (ZOL) is a potent antiresorptive agent that increases bone mineral density (BMD) and reduces fracture risk in postmenopausal osteoporosis (PMOP). The anti-osteoporotic effect of ZOL is determined by annual BMD measurement. In most cases, bone turnover markers function as early indica...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiang, Wang, Zi-Yuan, Ren, Na, Wei, Zhan-Ying, Hu, Wei-Wei, Gu, Jie-Mei, Zhang, Zhen-Lin, Yu, Xiang-Tian, Wang, Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166846/
https://www.ncbi.nlm.nih.gov/pubmed/37180703
http://dx.doi.org/10.3389/fphar.2023.1084453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166846/
https://www.ncbi.nlm.nih.gov/pubmed/37180703
http://dx.doi.org/10.3389/fphar.2023.1084453

Ejemplares similares